Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
      Description

      This study will evaluate the safety, tolerability, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with capecitabine and oxaliplatin in adults with relapsed/refractory metastatic pancreatic ductal adenocarcinoma.

      Conditions
      Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
      Talk to us
      TERMINATED
      Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma
      Description

      The primary objective of this study is to evaluate the safety of single agent idelalisib and to evaluate safety and define the maximum tolerated dose (MTD) of idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma.

      Conditions
      Previously Untreated Pancreatic Ductal AdenocarcinomaRelapsed/Refractory Pancreatic Ductal Adenocarcinoma
      Talk to us
      RECRUITING
      A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
      Description

      A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

      Conditions
      Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung CancerCervical CancerCastrate Resistant Prostate CancerPancreatic Ductal AdenocarcinomaHead-and-neck Squamous Cell CarcinomaEndometrial CancerOvarian CancerGastric CancerGastroesophageal-junction CancerUrothelial Carcinoma
      Talk to us
      TERMINATED
      Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
      Description

      The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.

      Conditions
      Neoplasm Metastasis
      Talk to us